CapsoVision (CV) Amortization of Deferred Charges (2024 - 2025)
CapsoVision (CV) reported Amortization of Deferred Charges of $91000.0 for Q4 2025, up 12.35% on a YoY basis from $81000.0 in Q4 2024, and up 2.25% sequentially from $89000.0 in Q3 2025.
CapsoVision (CV) Amortization of Deferred Charges (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of Amortization of Deferred Charges data on file, last reported at $91000.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges rose 12.35% year-over-year to $91000.0; the trailing twelve-month figure through Dec 2025 stood at $340000.0 (changed N/A YoY), and the FY2025 full-year result was $351000.0, up 11.43% from the prior year.
- Amortization of Deferred Charges improved to $91000.0 in Q4 2025, from $89000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $91000.0 in Q4 2025 to a low of $79000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 91,000.00 |
| Dec 31, 2025 | 91,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Sep 30, 2024 | 79,000.00 |